Myeloproliferative Disorders Drugs/Treatment Market, Report 2032

The myeloproliferative disorders drugs/treatment market size crossed USD 9.3 billion in 2023 and is set to expand at around 3.2% CAGR from 2024 to 2032, driven by the increasing availability of novel drugs and a robust pipeline that has broadened the treatment options and stimulated innovation for rare disease treatment.

2023年，骨髓增殖性疾病药物/治疗市场规模已突破93亿美元，预计从2024年至2032年将以约3.2%的复合年增长率持续扩张。这一增长动力源于创新药物的可获得性不断提升，以及一条稳健的研发管线，该管线拓展了治疗选择并激发了罕见病治疗的创新。